{"sentence_labels": [-1, -1, 1, -1, -1, -1], "text": "(documented by echocardiography) on stable treatment for chronic HF were considered eligible. Patients enrolled were stratified into 3 subgroups (age 6 to 12 months, >1 year and < 3 years, and 3 to 18 years), and were then randomly allocated to treatment with either ivabradine or placebo in a 2:1 ratio. Treatment was allocated via a centralized interactive randomization response system. The primary objectives of the study were to: 1) determine the optimal dose of ivabradine to reach a target heart rate reduction of $20% without bradycardia; and 2) assess the pharmacokinetic profile and pharmacokineticpharmacodynamic relationship of ivabradine in children. This report describes the results pertaining to the target heart rate reduction. Pharmacokinetic results have been reported in separate publications (19, 20) .", "section": "METHODS", "classification_label": 0, "section_number": 7, "sentences": ["(documented by echocardiography) on stable treatment for chronic HF were considered eligible.", "Patients enrolled were stratified into 3 subgroups (age 6 to 12 months, >1 year and < 3 years, and 3 to 18 years), and were then randomly allocated to treatment with either ivabradine or placebo in a 2:1 ratio.", "Treatment was allocated via a centralized interactive randomization response system.", "The primary objectives of the study were to: 1) determine the optimal dose of ivabradine to reach a target heart rate reduction of $20% without bradycardia; and 2) assess the pharmacokinetic profile and pharmacokineticpharmacodynamic relationship of ivabradine in children.", "This report describes the results pertaining to the target heart rate reduction.", "Pharmacokinetic results have been reported in separate publications (19, 20) ."], "doc_id": "34345"}